Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,255.77
(
-1.02%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: MRX22 post# 68577

Friday, 11/14/2008 6:25:18 PM

Friday, November 14, 2008 6:25:18 PM

Post# of 257580
>Teva still would have to bust the tenofovir patents to be able to sell generic Truvada.<

By filing a Paragraph-IV certification against Truvada based on only the Orange Book patents for Emtriva, Teva would seem to be implying that the Viread patents will be without force. Alternatively, GILD may not be divulging the full extent of Teva’s Paragraph-IV certifications. In any event, I’ll be interested in seeing the court pleadings when they come out. Regards, Dew

p.s. The quiz question in #msg-33586560 hinges on a different issue than the one above.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today